Immunologic Factor – Page 43

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

11 months ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.

Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success

11 months ago talkbio0Tagged China, CLEAR-1, Clinical Research, Dental Plaque, Innovent, interleukin-23, picankibart, Psoriasis, regulatory

Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study

AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup

11 months ago talkbio0Tagged AstraZeneca, Continuance of life, Daiichi, Datopotamab, Deruxtecan, Improvement, Malignant neoplasm of lung, Nonsquamous Non-Small Cell Lung Cancer, Phase 3 trial, Sankyo, TACSTD2 gene, therapeutic autologous dendritic cells

AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer

Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment

11 months ago talkbio0Tagged Antibodies, Bispecific, ASCO, Cancer Therapeutic Procedure, Expectations, investor, Merus

Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO

Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data

11 months ago talkbio0Tagged Biological Factors, Clinical Trials, head-to-head data, J&J, Psoriasis, Stelara, successor, Tremfya

J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.

AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody

11 months ago talkbio0Tagged AltruBio, Antibodies, Biotechnology, Cancer Therapeutic Procedure, healthcare innovation, Immune, Immunotherapy, Phase 2 Clinical Trials

AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.

Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

11 months ago talkbio0Tagged Disease remission, Effectiveness, guselkumab, Inflammatory Bowel Diseases, J&J, Johnson & Johnson, Maintenance, Phase 3 Clinical Trials, Safety, Tremfya, Ulcerative Colitis

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.

Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine

11 months ago talkbio0Tagged BioNTech, COVID19 (disease), Drug Industry, EPO, EU, European (ethnic group), Intellectual Property, Legal patent, Moderna, mRNA technology, Pfizer, Vaccines

Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.